Summary:
- Addex Therapeutics, a clinical-stage pharmaceutical company, has reported its financial results for the first half of 2024 and the second quarter of the year.
- The company provided an update on its corporate activities, including the progress of its drug development pipeline and ongoing collaborations.
- The report highlights Addex's focus on developing novel therapeutic approaches for the treatment of central nervous system disorders and other indications.